Current Report Filing (8-k)
April 18 2022 - 04:35PM
Edgar (US Regulatory)
0001053369 false 0001053369 2022-04-18
2022-04-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D)
OF
THE SECURITIES EXCHANGE ACT OF 1934
April 18, 2022
Date
of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada |
|
001-15697 |
|
22-3542636 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification No.) |
165 Ludlow Avenue,
Northvale,
New Jersey
07647
(Address
of principal executive offices)
(201)
750-2646
(Registrant’s
telephone number, including area code)
|
|
|
(Former
name or former address, if changed since last report.) |
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock, par value $0.001 per share |
|
ELTP |
|
OTCQB |
|
Item
5.02 |
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers. |
On
April 14, 2022, Marc Bregman notified Elite Pharmaceuticals, Inc.
(the “Company”) of his intent to leave the Company and resign from
his position as Chief Financial Officer, Treasurer and Secretary to
pursue another opportunity. Mr. Bregman’s last day with the Company
will be April 29, 2022.
In
addition to the titles discussed above, Mr. Bregman is the
Company’s Principal Financial Officer and Principal Accounting
Officer. The Company has commenced a search for Mr. Bregman’s
replacement.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, as
amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
ELITE
PHARMACEUTICALS, INC. |
| |
(Registrant)
|
|
|
|
|
|
Dated:
April 18, 2022 |
By: |
/s/
Nasrat
Hakim |
| |
Name: |
Nasrat
Hakim |
| |
Title: |
President
and CEO |
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Jun 2022 to Jul 2022
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Jul 2021 to Jul 2022
